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Abstract
Background: The National Kidney Foundation has formulated clinical practice guidelines for
patients with chronic kidney disease (K/DOQI). However, little is know about how many patients
actually achieve these goals in a dedicated clinic for chronic kidney disease.
Methods: We performed a cross-sectional analysis of 198 patients with an estimated glomerular
filtration rate of less than 30 ml/min/1.73 m2 and determined whether K/DOQI goals were met for
calcium, phosphate, calcium-phosphate product, parathyroid hormone, albumin, bicarbonate,
hemoglobin, lipids, and blood pressure.
Results: We found that only a small number of patients achieved K/DOQI targets. Recent referral
to the nephrologist, failure to attend scheduled clinic appointments, African American ethnicity,
diabetes, and advanced renal failure were significant predictors of low achievement of K/DOQI
goals.
Conclusion: We conclude that raising awareness of chronic kidney disease and K/DOQI goals
among primary care providers, early referral to a nephrologist, the exploration of socioeconomic
barriers and cultural differences, and both patient and physician education are critical to improve
CKD care in patients with Stage 4 and 5 CKD.
Background
The National Kidney Foundation has recently launched a
major effort to define Chronic Kidney Disease (CKD) and
formulate clinical practice guidelines [1,2]. It has been
clearly shown that complications of CKD, such as anemia,
metabolic acidosis, nutritional deficits, secondary hyper-
parathyroidism, and hypertension, significantly contrib-
ute to morbidity and mortality [3-10]. It has been
proposed that care for patients with CKD be best delivered
in dedicated CKD clinics that provide a multidisciplinary
approach to patients with CKD [11,12]. Typically, these
clinics are staffed with nephrologists, dieticians, social
workers, and educators, and the team works closely with
vascular surgeons for access placement. However, little is
known about the effectiveness of these clinics at academic
centers. The purpose of this cross-sectional analysis is
determine to what extent K/DOQI goals are achieved in a
dedicated CKD clinic serving a urban, socio-economically
disadvantaged minority population.
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Methods
Patients
IRB approval for this study was obtained from the Human
Subjects Research Office of the University of Miami,
Miami, FL (protocol number 2004–3071). All study pro-
cedures were carried out in accordance with the Declara-
tion of Helsinki regarding research involving human
subjects. Our chronic kidney disease (CKD) clinic focuses
on the care of patients with an estimated GFR, using the
modified MDRD formula [1], of less than 30 ml/min/1.73
m2 (Stage 4 and 5). The clinic setting is described in more
detail below. We screened 268 patients with an appoint-
ment scheduled between January and August of 2004 in
the CKD clinic at Jackson Memorial Hospital, Miami, FL.
Of those, 35 were excluded because they were not seen: 25
had already started renal replacement therapy, 1 patient
had died, and 9 patients were lost to follow-up. Of the
remaining 233 patients, an additional 35 were excluded:
7 patients did not have any laboratory data and thus the
degree of their renal impairment could not be deter-
mined, and 28 patients had CKD Stages 1, 2 or 3 after hav-
ing recovered from an episode of acute renal failure
(Figure 1). No dialysis patients were included in this
study. For patients who initiated renal replacement ther-
apy during the study period, their last pre-dialysis param-
eters were used for analysis.
Dedicated CKD clinic
All patients with Stages 4 or 5 CKD are followed in our
dedicated CKD clinic. The clinic is located in an urban
county hospital that predominantly serves socio-econom-
ically disadvantaged minority populations. The clinic
takes place once a week. The clinic is staffed by two aca-
demic nephrologists and four senior nephrology fellows,
a nurse practitioner, a social worker, a nurse educator, a
case manager, a dietician, and a pharmacist. Patients with
stage 4 CKD are seen by a physician at least every 3
months, more frequently if they have laboratory abnor-
malities or uncontrolled blood pressure. Patients with
stage 5 CKD are seen monthly. Patients receiving
Recruitment Figure 1
Recruitment. 268 patients had an appointment in the CKD clinic. Of those, 233 patients were seen at least once during the 
study period, and 198 met inclusion criteria.
268 patients with clinic
appointment between 
01/01/2004 – 08/31/2004
35 “no shows” 
25 started renal
  replacement  therapy
 1  death
9 lost to follow-up 
233 patients screened 
7 without laboratory data 
28 with CKD stages 1-3 
198 patients included 
61 seen  6 months 137 seen > 6 months 
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recombinant erythropoietin for anemia or active vitamin
D for secondary hyperparathyroidism are seen monthly
by the nurse practitioner. The nurse educator gives a short
lecture about dialysis options, vascular access, and com-
plications of CKD at the beginning of each clinic session.
In addition, one-on-one educational sessions are offered
to patients who decide on a dialysis modality. The dieti-
cian accepts walk-in appointments during regular CKD
clinic hours in addition to elective appointments for
nutritional counseling. The case manager assists with
referrals and follow-up appointments. The social worker
assists mainly with financial issues, since most of our
patients belong to socio-economically disadvantaged
minority populations, as well as referrals to the transplant
center. The pharmacist is available to answer patients'
questions about their medications, drug and food interac-
tions, adverse events, as well as programs offering finan-
cial assistance.
Nephrology fellows act as the patients' primary nephrolo-
gist. Each case is discussed with a staff nephrologist. Fol-
lowing a checklist, current data for core indicators for
CKD care including anemia, calcium, phosphate and PTH
metabolism, nutrition, metabolic acidosis, hyperlipi-
demia, blood pressure, and dialysis options including vas-
cular access, are compared to target values. Algorithms are
in place to start and adjust phosphate binders, calcium
supplements, active vitamin D preparations, recombinant
erythropoietin, iron supplementations, and to make deci-
sion regarding vascular access placement and transplant
referral. These algorithms are based on published treat-
ment guidelines [2,13-15]. K/DOQI guidelines do not
contain treatment recommendations for low HDL, which
we commonly treat with extended-release niacin.
Laboratory data are obtained quarterly for patients with
stage 4 CKD and monthly for patients with stage 5 CKD.
In patients not at goal, and in those receiving active vita-
min D preparations or recombinant human erythropoie-
tin supplementation, data are obtained monthly, and
medication doses are adjusted accordingly.
The nephrology clinics receive referrals mostly from pri-
mary care providers (PCP), internists, cardiologists, and
endocrinologists practicing within the hospital system
and its affiliated community clinics. All referrals are
triaged by their estimated GFR: patients with stage 4 or 5
CKD are directly seen in the CKD clinic, while all others
are seen in the general nephrology clinic. PCP are strongly
encouraged to refer all patients with Stage 3 CKD, or
whenever there is a doubt in regards to diagnosis or ther-
apy. During the study period, of the patients seen for the
first time in the CKD clinic about half came from the gen-
eral nephrology clinic with progressive renal failure, while
the other half were new referrals. In patients seen in the
nephrology clinics who reach Stage 4 CKD the nephrolo-
gist typically manages all problems related to chronic kid-
ney disease.
Data collection
Laboratory parameters for serum calcium, phosphate,
intact PTH, albumin, bicarbonate, and hemoglobin were
obtained from chart review. For each patient, the most
recent value prior to their last clinic appointment within
the study period was used. Laboratory data had to be
obtained no more than 3 months prior to the patients
scheduled visit, otherwise they were entered as "not at
goal". This is based on the K/DOQI recommendation to
obtain laboratory data for the parameters investigated in
this study at least quarterly. The serum calcium concentra-
tion was corrected for serum albumin using the formula
[Cacorrected] = [Cameasured] + 0.8 × (4 - [Albumin]), where
[Ca] is expressed in mg/dl and [Albumin] is expressed in
g/dl [16]. The calcium-phosphate product was obtained
by multiplying the corrected serum calcium with the
serum phosphate concentration and expressed as mg2/dl2.
The following treatment targets were used for patients
with CKD Stages 4 and 5, respectively [2,13-15]: calcium
8.4–10.3/8.4–9.5 mg/dl, phosphate 2.7–4.6/3.5–5.5 mg/
dl, and intact PTH 70–110/150–300 pg/ml. Identical
treatment targets were set for patients with CKD Stage 4
and 5, respectively, for calcium-phosphate product (<55
mg2/dl2), albumin (≥3.5 g/dl), bicarbonate (>22 mmol/
l), hemoglobin (≥ 11 g/dl), and blood pressure (less than
130/80 mmHg). The goals for lipid control were set at
LDL < 100 mg/dl, triglycerides < 500 mg/dl, and non-
HDL < 150 mg/dl. If any of the three lipid goals was not
met, the subject was classified as "not at goal". Thus, a
total of nine parameters were evaluated: 8 laboratory
parameters plus blood pressure. Patient age, gender, eth-
nicity, and the following co-morbidities were abstracted
from chart review: diabetes, hypertension, and hyperlipi-
demia. Failure to attend scheduled clinic visits half the
time or more (no show rate ≥ 50%) was used as a surro-
gate measure of non-adherence. The length of nephrology
care in months was tabulated; time spent in the CKD
clinic, the general nephrology clinic, or under the care of
a nephrologist in private practice was added. Patients who
had been seen for 6 months or less by a nephrologist were
categorized as having received short nephrology care
(SNC), while all others were categorized having received
long nephrology care (LNC).
Statistical analysis
All statistical analyses ware carried out using the SPSS sta-
tistical software package (SPSS Inc., Chicago, IL). We
chose poor achievement of K/DOQI goals as the outcome
variable, which was defined as having less than half the
parameters, i.e., 0 to 4 out of 9, at goal, because we felt
that it is clinically relevant if a patient has more than halfBMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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of the investigated parameters not at goal. Categorical var-
iables were compared by chi square analysis. Continuous
variables were compared with Student's t-test if two
groups were present or ANOVA followed by post hoc anal-
ysis if more than two groups were present. Welch's correc-
tion for unequal variances and Bonferroni's correction for
multiple testing were employed where indicated. Associa-
tions were tested by logistic regression. The following var-
iables were thought to be clinically relevant and entered
into the model: age (converted into decades), gender, Afri-
can American ethnicity, short nephrology care (SNC), fail-
ure to attend scheduled clinic visits (no show rate above
Table 1: Patient characteristics
All (N = 198) LNC† (N = 146) SNC† (N = 52) P-value
Ethnicities
Hispanic 46% 44% 54% 0.214
African American 43% 48% 31% 0.032
Haitian 7% 7% 8% 0.839
Caucasian 3% 1% 5% 0.083
A s i a n 1 %0 %2 % 0 . 0 9 3
Age [Years]
Mean ± SD 56 ± 13.4 51 ± 14 58 ± 12.7 0.001
<31 4% 1% 10% 0.006
31–40 10% 8% 14% 0.270
41–50 20% 19% 21% 0.758
51–60 25% 23% 31% 0.241
61–70 28% 32% 17% 0.041
71–80 12% 13% 8% 0.304
> 8 0 3 %3 %2 % 0 . 1 7 6
Gender
Female 53% 55% 48% 0.405
CKD Stage
Stage 4 47% 48% 44% 0.645
Length of Nephrology Care [Months]
0–1 9% 0% 35% -
2–6 17% 0% 65% -
7–12 14% 20% 0% -
13–24 15% 22% 0% -
24–36 15% 21% 0% -
>36 30% 44% 0% -
Co-Morbidities
Hypertension 92% 95% 83% 0.004
Hyperlipidemia 66% 71% 52% 0.015
Diabetes 50% 45% 65% 0.008
Estimated GFR at Referral to Nephrology [ml/min/1.73 m2]
Mean ± SD 26 ± 14.9 29 ± 15.7 17 ± 8.3 <0.001
<15 21% 13% 42% <0.001
15–29 52% 51% 52% 0.945
30–59 24% 31% 6% <0.001
> 5 9 4 %5 %0 % 0 . 1 0 8
† LNC: seen by a nephrologist for more than 6 months; SNC: seen by a nephrologist for 6 months or less. Data for LNC and SNC were compared 
using Chi Square Analysis for categorical variables or by unpaired t-test for continuous variables. Welch's correction was used if unequal variances 
were present.BMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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50%), stage 5 CKD, diagnosis of diabetes, hypertension,
and hyperlipidemia.
Results
Patient characteristics
Patient characteristics are shown in Table 1. Median fol-
low-up time for SNC patients was 2 months, while the
median follow-up for LNC patients with nephrology care
was 33 months. 44% of LNC patients had been followed
for 3 years or more. Important differences between LNC
patients and SNC were noted. There were fewer African
Americans and more young patients among SNC patients.
SNC patients were less likely to carry the diagnosis of
hypertension and hyperlipidemia but more likely to have
diabetes. About 43% of the patients were poor and unin-
sured, 18% had Medicaid only, and 26% had Medicare as
their primary insurance. There was no difference in insur-
ance status between SNC or LNC patients (data not
shown).
Achievement of K/DOQI goals
The median values along with the 25th and 75th percentiles
for estimated GFR, serum calcium, phosphate, calcium-
phosphate product, intact PTH, bicarbonate, albumin,
hemoglobin, lipids, and blood pressure are shown in
Table 2. The proportion of patients achieving K/DOQI
goals are shown in Table 3.
Except for SNC patients with Stage 5 CKD more than 80%
of all patients achieved calcium goals. Those outside the
target range were more likely to have low calcium levels
suggesting secondary hyperparathyroidism; calcium levels
above target range were rare.
80% of LNC patients with Stage 4 CKD had phosphate
levels at goal, and only 1 patient had a serum phosphate
above 6 mg/dl. Only 66% of LNC patients with Stage 5
CKD had phosphate levels within the target range, 22%
had phosphate levels above 6 mg/dl, and 13% had phos-
phate levels above 7 mg/dl. The highest phosphate level in
this group was 10.5 mg/dl. Among SNC patients, only
about half of all patients achieved phosphate goals, and
13% with Stage 4 CKD and 24% with Stage 5 CKD had
phosphate levels above 6 mg/dl. None of these patients
had serum phosphate levels above 7 mg/dl, suggesting a
shorter disease course or poorer nutrition.
Given the relative high percentage of patients with low
calcium concentrations, calcium-phosphate products
were within target range for more than three quarters of all
patients. The lower percentage of SNC patients with Stage
4 CKD achieving goal is due to the high number of miss-
ing data that were coded as not at goal. Missing data
resulted from missing phosphate determinations.
Secondary hyperparathyroidism presented a serious prob-
lem in our cohort. Only between 9% and 24% of all
patients achieved PTH goals. Among those with Stage 4
CKD who had a PTH determination on file, PTH levels
were below target in 6%, 41% were at goal, 110–200 pg/
Table 2: Mean laboratory parameters and blood pressure values
Stage 4 CKD Stage 5 CKD
SNC† (N = 23) LNC† (N = 70) SNC† (N = 29) LNC† (N = 76) p-values
Estimated GFR [ml/min/1.73 m2] 22 ± 4* 21 ± 4# 9.1 ± 3* 9.1 ± 3# *#<0.001
Calcium [mg/dl] 9.5 ± 0.6 9.3 ± 0.6* 8.9 ± 0.9 8.9 ± 0.8* *0.015
Phosphate [mg/dl] 4.6 ± 1.1 4.1 ± 0.9* 5.2 ± 1.2 5.3 ± 1.5* *<0.001
Calcium-Phosphate Product [mg2/dl2] 45 ± 11 38 ± 9*# 46 ± 10# 47 ± 13* *<0.001; #0.035
iPTH [pg/ml] 155 ± 153* 203 ± 152# 532 ± 476* 486 ± 385# *0.008; #<0.001
Bicarbonate [mmol/l] 23 ± 4 25 ± 4*# 21 ± 5# 21 ± 4* *#<0.001
Albumin [g/dl] 3.3 ± 0.8 3.8 ± 0.5 3.5 ± 0.7 3.6 ± 0.6
Hemoglobin [g/dl] 11.3 ± 2.0 11.8 ± 1.2*# 10.3 ± 1.9# 10.5 ± 1.8* *<0.001; #0.003
Total Cholesterol [mg/dl] 190 ± 37 189 ± 40 180 ± 56 172 ± 41
Triglycerides [mg/dl] 153 ± 72 176 ± 120 183 ± 115 149 ± 85
LDL [mg/dl] 111 ± 30 103 ± 34 100 ± 49 94 ± 33
HDL [mg/dl] 48 ± 16 53 ± 15* 43 ± 15* 47 ± 16 *0.033
Non-HDL [mg/dl] 142 ± 38 137 ± 39 137 ± 54 125 ± 37
Systolic Blood Pressure [mmHg] 148 ± 27 135 ± 26* 155 ± 27* 147 ± 28
Diastolic Blood Pressure [mmHg] 82 ± 21 73 ± 14* 84 ± 17* 77 ± 16 *0.049
Shown are the most recent data obtained within the 3-months period preceding the last clinic visit. All data are shown as mean ± standard 
deviation. Stage 4 = GFR 15–29, Stage 5 = GFR <15 ml/min/1.73 m2. The glomerular filtration rate was estimated using the modified MDRD formula 
[1]. † SNC: nephrology care for 6 months or less; LNC: nephrology care for more than 6 months. Data in each row were analyzed by one-way 
ANOVA followed by pair wise post hoc comparisons. Welch's correction for unequal variances was used where indicated. Bonferroni's correction 
for multiple comparisons was applied within each row. Pairs compared in each row bear the same symbol. Only p < 0.05 are shown.BMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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ml in 24%, 200–400 pg/ml in 24%, and above 400 pg/ml
in 5% of the patients. None of the patients with Stage 4
CKD had PTH levels above 1000 pg/ml. For those with
Stage 5 CKD who had a PTH determination on file, PTH
levels were below target in 15%, at goal in 29%, 300–600
pg/dl in 28%, 600–900 pg/ml in 17% and above 900 pg/
ml in 11% of the patients. Particularly in SNC patients,
missing PTH determinations that were coded as not at
goal resulted in the overall very low number of patients
achieving PTH targets.
Between 70% and 80% of patients with Stage 4 CKD had
good control of metabolic acidosis, while only 38% to
49% of patients with Stage 5 CKD had adequate bicarbo-
nate levels. There was no significant difference between
SNC and LNC patients.
Albumin was chosen as a surrogate marker for malnutri-
tion. A higher proportion of LNC patients had normal
serum albumin concentrations than SNC patients; how-
ever, this difference was no longer significant in patients
with Stage 5 CKD. 9% of LNC patients with Stage 4 CKD
and 13% of LNC patients with Stage 5 CKD had albumin
concentrations below 3 g/dl. For SNC patients, the corre-
sponding proportions were 35% and 24%, respectively.
More than three quarters of LNC patients with Stage 4
CKD had adequate anemia management, while only 57%
of SNC patients with Stage 4 CKD had desirable hemo-
globin concentrations. Hemoglobin concentrations for
LNC patients with Stage 4 CKD were between 9 and 10 g/
dl in 6%, and between 10 and 11 g/dl in 17% of the cases,
while for SNC patients they were below 9 g/dl in 9%,
between 9 and 10 g/dl in 17%, and between 10 and 11 g/
dl in 17% of the cases. Anemia control was worse in
patients with stage 5 CKD. For SNC patients and LNC
patients hemoglobin concentrations were below 9 g/dl in
21% and 16%, between 9 and 10 g/dl in 28% and 17%,
and between 10 and 11 g/dl in 14% and 24% of the cases,
respectively.
Hypertriglyceridemia was uncommon in all groups.
While only about half of all patients achieved an LDL of
less than 100 mg/dl, 64% had an LDL less than 110 mg/
dl and 79% had an LDL of less than 130 mg/dl. Total cho-
lesterol levels tended to be lower in patients with Stage 5
CKD, leading to a greater proportion of patients with non-
HDL cholesterol at goal.
Blood pressure control was poor in all groups. Stage 1
hypertension [17] was present in 27% and 37% of LNC
patients with Stages 4 and 5 CKD, respectively, and in
30% and 52% of SNC patients with Stages 4 and 5 CKD,
respectively. Stage 2 hypertension [17] was present in
14% and 28% of LNC patients with Stages 4 and 5 CKD,
respectively, and in 35% and 34% of SNC patients with
Stages 4 and 5 CKD, respectively. Overall, the prevalence
of stage 1 or stage 2 hypertension combined was 82% in
SNC and 44% in LNC patients (p < 0.003)
Table 4 shows the percentage of patients with 0–1, 2–3, 4–
5, 6–7, and 8–9 of the nine investigated parameters at
goal. As became already evident in table 3, our results
indicate that LNC patients with Stage 4 CKD who had
been seen by a nephrologist for more than 6 months were
more likely to achieve goals than SNC patients seen for 6
Table 3: Proportion of patients achieving K/DOQI targets
Stage 4 CKD Stage 5 CKD
SNC† (N = 23) LNC† (N = 70) p-value SNC† (N = 29) LNC† (N = 76) p-value
Calcium 87% 91% 0.529 79% 82% 0.791
Phosphate 48% 80% 0.003 52% 66% 0.185
Calcium-Phosphate Product 65% 94% <0.001 83% 78% 0.789
iPTH 9% 20% 0.213 24% 21% 0.733
Bicarbonate 70% 81% 0.230 38% 49% 0.323
Albumin 43% 76% 0.004 48% 62% 0.208
Hemoglobin 57% 77% 0.056 38% 42% 0.697
Lipids 35% 49% 0.249 34% 49% 0.191
Triglycerides 91% 94% 0.614 90% 96% 0.207
LDL 39% 53% 0.253 48% 55% 0.521
Non-HDL 52% 63% 0.253 66% 76% 0.249
Blood Pressure 17% 34% 0.132 10% 17% 0.382
Shown are the percentages of patients in each group with laboratory values within K/DOQI target ranges. Laboratory data were the most recent 
values within the 3 months period preceding the last clinic visit. See methods section for individual ranges. Stage 4 = GFR 15–29, Stage 5 = GFR <15 
ml/min/1.73 m2. The glomerular filtration rate was estimated using the modified MDRD formula [1]. † LNC: seen by a nephrologist for more than 6 
months; SNC: seen by a nephrologist for 6 months or less. Data for LNC and SNC were compared using Chi Square Analysis. Only p-values < 0.05 
are shown.BMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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months or less. In Stage 5 CKD patients, length of neph-
rology care did not appear to make a big difference. Over-
all, only a very small fraction of all patients had eight or
nine parameters at goal.
Predictors of low achievement of K/DOQI goals
We used logistic regression to determine predictors for the
failure to achieve K/DOQI goals (Figure 2). The following
variables were entered into the model: failure to attend
scheduled clinic appointments (no show rate ≥50% ver-
sus <50%), having received short nephrology care (≤6
months versus >6 months), CKD Stage 5 (versus CKD
Stage 4), African American ethnicity (versus all others),
age below 60 years (versus ≥60), female gender (versus
male), and having (versus not having) diabetes, hyperten-
sion or hyperlipidemia. In addition, all two-way interac-
tion terms were considered; however, no interactions were
detected. Short nephrology care (OR = 3.3), failure to
attend scheduled clinic appointments (OR = 3.2), African
American background (OR = 2.2), diabetes (OR = 2.2),
and Stage 5 CKD (OR = 2.2) were significant predictors of
low achievement of K/DOQI goals. Age, gender, hyperlip-
idemia, and hypertension did not reach the level of signif-
icance set as p < 0.05.
Discussion
Dedicated CKD clinics have been established based on the
conviction that such clinics will help implement K/DOQI
goals and thus improve outcomes [11,18]. Recent data
show that multidisciplinary pre-dialysis care is associated
with significantly lower mortality after starting dialysis
[19]. However, in this study, Curtis et al also report that
anemia management only achieved a mean hemoglobin
of 102 ± 18 g/l in the multidisciplinary group at the time
dialysis was initiated. This is comparable to our results
achieved in patients with stage 5 CKD (median: 10.5 mg/
dl) and falls short of K/DOQI goals. Similar to our
findings, preliminary data from the United Kingdom
showed difficulties in achieving K/DOQI goals [20]: in
patients with stage 4 and stage 5 CKD, blood pressure
goals were achieved in 22.2% and 16.9%, and bicarbo-
nate goals in 41.2% and 29.7%, respectively. Achievement
of PTH and hemoglobin goals was better in that study,
however, cut-off values were different from the ones rec-
ommended by K/DOQI, making a direct comparison dif-
ficult. Thus, it appears that although there are proven
benefits of having CKD clinics, outcomes might be
improved even further if a better achievement of K/DOQI
goals could be realized. We found that several factors can
be identified that contribute to our failure to reach K/
DOQI targets in a larger number of patients.
For most of the parameters investigated, SNC patients
with Stage 4 CKD were less likely to achieve goals than
LNC patients. Since our referral sources are PCP working
either out of the main campus or affiliated satellite clinics,
our findings raise the hypothesis that PCP may not be
familiar with CKD and its associated co-morbidities. This
is most evident in the finding that more than half the
patients referred from PCP did not have their PTH level
checked, and a quarter had no phosphate determinations
on record. The observation that about 25% of the cohort
in this study represented SNC patients, i.e., patients
referred to the nephrologist for the first time when they
already had Stage 4 or 5 CKD, corroborates this impres-
sion. The prevalence of CKD is high and with the rising
incidence of diabetes it is not expected to decrease [21].
Thus, it will be of vital importance to include the PCP in
Table 4: Proportion of patients achieving a set number of K/DOQI targets
Stage 4 CKD# Stage 5 CKD#
Parameters at goal* SNC† (N = 23) LNC† (N = 70) p-value SNC† (N = 29) LNC† (N = 76) p-value
0–1 0% 0% 0% 5%
2–3 39% 3% 34% 28%
4–5 26% 30% 52% 26%
6–7 35% 54% 14% 36%
8–9 0% 13% 0% 5%
Mean ± SD 4.3 ± 1.8 6.0 ± 1.3 0.001 4.1 ± 1.4 4.6 ± 2.0 0.477
* Number of parameters shown in table 3 that are within the range recommended by K/DOQI. See methods section for individual ranges. Each row 
shows the proportion of patients within each category achieving the indicated number of parameters at goal. The last row shows the mean number 
of parameters at goal within each category. P-values were determined by ANOVA with Welch's correction for unequal variances followed by 
Tamhane's post hoc pairwise comparison of SNC and LNC within each Stage of CKD. # Stage 4 = GFR 15–29, Stage 5 = GFR <15 ml/min/1.73 m2. 
The glomerular filtration rate was estimated using the modified MDRD formula [1]. † SNC: seen for 6 months or less, LNC: seen for more than 6 
monthsBMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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the care of CKD patients and promote early screening,
early initiation of treatment, and timely nephrology refer-
ral [22,23]. Educating PCP about early CKD care will be
an important step in including them in the care of CKD
patients.
We found that the most difficult to manage parameter was
PTH; no more than 25% of the patients achieved K/DOQI
targets. Similar results were reported by others in dialysis
patients despite extensive use of active Vitamin D prepara-
tions [24]. A review of our patients' charts revealed that
virtually every patient with an elevated PTH was pre-
scribed active Vitamin D, with the exception of those with
elevated phosphate levels (above 5.5 mg/dl) or calcium-
phosphate products (above 55 mg2/dl2). However, Vita-
min D doses used were quite low compared to what is cus-
tomary in hemodialysis patients (data not shown). Thus,
the problems may not to be lack of use, but failure to uti-
lize the correct dose of active Vitamin D preparations,
even though an algorithm was in place. The preferred
active vitamin D preparation at this institution was oral
doxercalciferol. Based on the prevalence and severity of
observed hyperparathyroidism in our clinic and the dos-
age algorithm used, we expected an average dose of 1.49
micrograms daily in patients with stage 4 CKD and 1.75
micrograms daily in patients with stage 5 CKD. The
observed dose in patients that did receive active vitamin D
was about 25% lower than the expected dose. "Clinical
inertia" on the part of clinicians, which has been reported
in the care of patients with other chronic diseases such as
diabetes, may represent a significant problem [25], as well
as concerns about adynamic bone disease, even though
this condition is uncommon in the pre-dialysis popula-
tion [26-29]. In addition, patients referred late by the PCP
may already have hyperplasia of the hyperparathyroid
gland that is more difficult to treat than the hypertrophy
seen earlier in the course of the disease. Finally, we
noticed that a number of patients did not understand the
difference between over-the-counter vitamin preparations
and active Vitamin D. Taken together these data suggest
that both physician and patient education are critical
components of CKD care. In light of a recent report show-
ing that the combination of high PTH and normal serum
calcium and phosphate concentrations was associated
with the lowest mortality in prevalent hemodialysis
patients [6], prospective studies correlating PTH levels
with outcomes in pre-dialysis patients are needed.
Patients with Stage 5 CKD were less likely to achieve K/
DOQI targets when compared to patients with Stage 4
CKD. In fact, the benefit of LNC was virtually lost among
patients with stage 5 CKD. Among those with Stage 5
CKD, patients requiring renal replacement therapy had
the worst results (data not shown). One might argue that
the renal team initiates renal replacement therapy too late,
i.e., dialysis is only started at a point when medical man-
agement becomes impossible. We noted that a number of
patients in our clinic are very reluctant to initiate renal
replacement therapy in the absence of severe uremic
symptoms despite intense counseling. In fact, only half
the patients with a GFR of less than 10 ml/min/1.73 m2
started renal replacement therapy. There are no strong
Logistic regression analysis to identify predictors of poor achievement of K/DOQI Goals Figure 2
Logistic regression analysis to identify predictors of poor achievement of K/DOQI Goals. The outcome was 
defined as having less than five of the nine parameters shown in Table 3 at goal. Shown are the odds ratio (OR), 95% confi-
dence interval (CI), and p-value. All 2-way interaction terms were tested and no interaction was detected. Thus, interaction 
terms were excluded from the full model. All variables entered are shown. Short nephrology care (SNC) was defined as having 
been seen by a nephrologist for 6 months or less. African Americans were compared to all other ethnicities. No show ≥ 50% 
indicates failure to attend scheduled clinic appointments at least half the time. Age was entered after transformation into 
decades.
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data to suggest that an earlier start of dialysis is beneficial
[30-33], however, there is data to suggest that treatment
goals for complications of CKD such as anemia are more
frequently achieved after initiation of hemodialysis [21].
It is possible that this is secondary better adherence since
many medications, such as erythropoiesis-stimulating
agents, iron, or active vitamin D preparations, are admin-
istered in intravenous form during the hemodialysis ses-
sion. In addition, regular, mandatory clinical quality
assurance measures in dialysis units may lead to a stricter
adherence to treatment protocols. Thus, in the CKD pop-
ulation, additional vigilance may be needed in patients
approaching the need for renal replacement therapy to
achieve better outcomes.
Our finding that failure to attend scheduled clinic
appointments, younger age, and being African American
were all associated with the failure to achieve K/DOQI
goals may suggest that cultural or socioeconomic barriers
exist. Prior studies investigating access to nephrology care
have reported similar findings [34,35]. It is interesting to
note that a large proportion of Hispanic patients have a
poor command of English, yet being African American
conferred a higher risk of not achieving K/DOQI goals,
suggesting that language per se may not be a barrier for
successful CKD care.
Hyperlipidemia was associated with a better achievement
of K/DOQI goals, although statistical significance was not
reached. This was surprising since hyperlipidemia has
been associated with higher cardiovascular morbidity and
mortality, and has been postulated to promote faster pro-
gression of renal failure. For this reason, we expected the
opposite association. However, since virtually all patients
in our cohort carrying the diagnosis of hyperlipidemia are
treated with a HMG-CoA reductase inhibitor, we hypoth-
esize that it may be the treatment for, rather than the diag-
nosis of hyperlipidemia that promotes achievement of K/
DOQI goals. Additional research is needed to explore this
possibility.
A significant number of variables associated with failure
to achieve K/DOQI goals were patient characteristics, such
as failure to attend clinic appointments, younger age, and
African American ethnicity. This is an important observa-
tion, because physician profiling is gaining momentum as
a way to improve quality of patient care and adherence to
practice guidelines [36]. Our data show that it may be very
difficult to judge physicians' performances based on
report cards derived from a set of laboratory data that are
compared to published practice guidelines, without tak-
ing into account the characteristics of the patient
population.
Limitations of the study
Our study has several important limitations. Given that
this is a single center study, our population has a unique
ethnic mix, which may make it difficult to compare our
results with what is seen at other centers. However, minor-
ities are among the fastest growing segments in the United
States population, and minorities have the highest inci-
dence and prevalence of chronic kidney disease and end-
stage renal disease [37]. Thus, it is of vital importance to
focus on the health needs of these populations. The pop-
ulation size is small in comparison to some of the pub-
lished data from managed care providers [38]. This may
decrease our power to detect parameters associated with a
poorer outcome. However, our study identified important
predictors of poor outcomes that can be targeted in future
prospective studies. We chose the most recent laboratory
value rather than the mean of a number of tests. Thus,
patients who had a recent worsening of their status, for
example due to hospitalization, may inadvertently have
been classified as 'not at goal'. However, averaging several
values may have introduced a bias as well, since SNC
patients are expected to have a trend towards improve-
ment. Being a retrospective analysis, our data only show
associations and do not reveal causalities. Thus, the
hypotheses generated by this study will need to be tested
prospectively. We have initiated a prospective clinical
study to address several of the key points raised by the cur-
rent work, such as raising the awareness of CKD among
referring physicians, frequent quality checks and direct
feed back to providers to avoid "clinical inertia", a modi-
fied teaching program for patients to improve the patient-
provider interaction and enhance empowerment, and
intensified case management to address socio-economic
barriers to CKD care. It is not known, and this study was
not designed to test, whether achieving K/DOQI goals will
improve or potentially worsen long-term-outcomes in
patients with Stages 4 and 5 CKD, such as cardiovascular
morbidity and mortality. Additional research is needed to
address this important question. Finally, it is likely that
the parameters collected from a given patient are not inde-
pendent. In addition, multiple interactions exist; for
example, the treatment of hyperphosphatemia may influ-
ence metabolic acidosis, the treatment of anemia may
affect hypertension, and well-nourished patients may
have a higher chance to develop hyperphosphatemia.
Given the small sample size in our study, we were not able
to identify predictors of poor outcomes for each category,
such as anemia, while adjusting for all other terms. While
it would be clinically important to test these scenarios,
this likely will require a multi-center effort.
Conclusion
In summary, we found that K/DOQI goals are achieved in
only a small proportion of patients cared for in a dedi-
cated CKD clinic. While numerous publications show thatBMC Nephrology 2005, 6:11 http://www.biomedcentral.com/1471-2369/6/11
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dedicated CKD clinics lead to better outcomes, it appears
that there is room for improvement. Raising awareness of
CKD and K/DOQI goals among PCP, early referral to a
nephrologist, timely initiation of renal replacement ther-
apy, the exploration of socioeconomic barriers and cul-
tural differences, and both continuous patient and
physician education are critical to improve CKD care. Pro-
spective clinical trials are needed to explore the impact of
these measures on cardiovascular morbidity and mortality
in the pre-dialysis arena.
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